ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas M. Beaver
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beaver, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beaver, T. M.
Related Collections
Right arrow Valve disease
Right arrowRelated Article

Ann Thorac Surg 2007;84:85-86
© 2007 The Society of Thoracic Surgeons


Original Articles: Cardiovascular

Invited commentary

Thomas M. Beaver, MD, MPH

Thoracic and Cardiovascular Surgery, University of Florida, 1600 SW Archer Road, Room NG-33, Gainesville, FL 32610

(Email: beavetm{at}surgery.ufl.edu).

In this article, Pai and colleagues [1] describe their institutional experience with aortic valve replacement in the setting of severe pulmonary hypertension. This is a follow-up study of two previous reports from these authors who are now focusing on the pulmonary hypertension cohort. This is a welcome addition to the surgical literature, as there is a paucity of data on this challenging patient population.

The mortality follow-up was obtained from social security numbers and the national death index. Accordingly it is difficult to discern to what degree surgeon selection bias may have played as a role in avoiding unsavory surgical candidates (eg, the patients undergoing aortic valve replacement [AVR] were often younger). Nonetheless, the 30-day mortality in nonoperated patients was striking at 30% compared with operated patients at 8%. Again, astute clinical judgment could partially explain the high early mortality in nonoperated patients and not as the authors suggest "a need for emergent AVR in these patients in view of a 1% per day mortality." However, when the authors stratified patients with propensity analysis according to the likelihood of undergoing AVR they demonstrated a significant survival benefit with surgery. Furthermore, when they censored the early deaths, which should remove those patients who would have been judged to be a prohibitive operative risk, a survival benefit still remained.

The good news for patients with pulmonary hypertension is that if they were successfully managed through surgery there were no significant differences in the Kaplan-Meier survival curves in the patients with severe pulmonary hypertension compared with those without it. The key then is how to safely guide these patients through their perioperative course. There are now numerous adjuncts available including intravenous milrinone, nesiritide, inhaled nitric oxide, and prostacyclin, and on the horizon, intravenous endothelin-1 antagonists. Our group and others have transitioned patients to oral phosphodiesterase inhibitors such as sildenafil [2, 3]. Much work remains to be done in identifying the optimal perioperative treatment strategies in randomized trials, and also in more accurate reporting to the national Society of Thoracic Surgeons’ database to better define the prevalence.

This report probably confirms most surgeons’ inherent bias that this patient group can be operated on with reasonable perioperative mortality. I encourage the authors to share their findings with the cardiology community. As the authors themselves noted, "The majority of decision[s] for nonsurgical management [were] made by the cardiologists in conjunction with the patients presumably assuming they were too sick for surgical therapy." As evidenced by this article, a huge survival benefit is accrued to those patients successfully managed through surgery and they should be counseled accordingly.


    References
 Top
 References
 

  1. Pai RG, Varadarajan P, Kapoor N, Bansal RC. Aortic valve replacement improves survival in severe aortic stenosis associated with severe pulmonary hypertension Ann Thorac Surg 2007;84:80-86.[Abstract/Free Full Text]
  2. Trachte A, Lobato EB, Urdanetta F, et al. Oral sildenafil as an adjunct in the treatment of pulmonary hypertension following cardiac surgery Ann Thorac Surg 2004;79:194-197.
  3. Klodell CT, Morey TE, Aranda JM, et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure and nitric oxide utilization in patients with left ventricular assist devices Ann Thorac Surg 2007;83:68-71.[Abstract/Free Full Text]

Related Article

Aortic Valve Replacement Improves Survival in Severe Aortic Stenosis Associated With Severe Pulmonary Hypertension
Ramdas G. Pai, Padmini Varadarajan, Nikhil Kapoor, and Ramesh C. Bansal
Ann. Thorac. Surg. 2007 84: 80-85. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas M. Beaver
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beaver, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beaver, T. M.
Related Collections
Right arrow Valve disease
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS